Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus...

Ogkologos - 24 Φεβρουαρίου, 2025

Abnormal Results from Prenatal Blood Test Could Point to Cancer in...

Ogkologos - 21 Φεβρουαρίου, 2025

FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle...

Ogkologos - 21 Φεβρουαρίου, 2025

EMA Recommends Granting a Marketing Authorisation for Datopotamab Deruxtecan

Ogkologos - 20 Φεβρουαρίου, 2025

FDA Approves Injectable Nivolumab, an Alternative to IV Infusion

Ogkologos - 19 Φεβρουαρίου, 2025

Zenocutuzumab Shows Efficacy in Patients with Advanced NRG1 Fusion-positive Cancers

Ogkologos - 19 Φεβρουαρίου, 2025

Many Men with Metastatic Prostate Cancer Are Not Getting the Recommended...

Ogkologos - 18 Φεβρουαρίου, 2025

Less Frequent Mammographic Surveillance Non-inferior Compared with Annual Mammograms After Diagnosis...

Ogkologos - 18 Φεβρουαρίου, 2025

First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR...

Ogkologos - 17 Φεβρουαρίου, 2025

EMA Recommends Granting a Marketing Authorisation for Tisotumab Vedotin

Ogkologos - 14 Φεβρουαρίου, 2025

1...575859...440 Σελίδα 58 από 440

MOST POPULAR

Beating cancer by improving the public’s health: the road ahead in...

4 Δεκεμβρίου, 2020

ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and...

20 Οκτωβρίου, 2020

New on NCI’s Websites for November 2024

1 Νοεμβρίου, 2024

Researchers Turn On PTEN Tumor-Suppressor Protein in Cancer Cells

14 Ιουνίου, 2019

Φόρτωση περισσοτέρων

Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus...

Abnormal Results from Prenatal Blood Test Could Point to Cancer in...

FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle...

EMA Recommends Granting a Marketing Authorisation for Datopotamab Deruxtecan

FDA Approves Injectable Nivolumab, an Alternative to IV Infusion

Zenocutuzumab Shows Efficacy in Patients with Advanced NRG1 Fusion-positive Cancers

Many Men with Metastatic Prostate Cancer Are Not Getting the Recommended...

Less Frequent Mammographic Surveillance Non-inferior Compared with Annual Mammograms After Diagnosis...

First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR...

EMA Recommends Granting a Marketing Authorisation for Tisotumab Vedotin

MOST POPULAR

Beating cancer by improving the public’s health: the road ahead in...

ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and...

New on NCI’s Websites for November 2024

Researchers Turn On PTEN Tumor-Suppressor Protein in Cancer Cells

HOT NEWS

NICE recommends pembrolizumab for 1,600 more people with breast cancer

Withdrawal of the Application to Change the EMA Marketing Authorisation for...

Whole-Genome Sequencing Provides Rapid and Accurate Genomic Profiling in Patients with...

Analysis Patterns of Systemic Anticancer Treatment at End-of-Life Indicates No Changes...

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ